Ligand Pharmaceuticals, Inc. (LGND) Reports Q4 Earnings of $0.24, Offers FY12 Sales Guidance
Ligand Pharmaceuticals, Inc. (NASDAQ: LGND) reported Q4 EPS of $0.24, versus $0.12 reported last year. Revenue for the quarter came in at $12.9 million, versus $3.9 million reported last year.
For 2012, Ligand currently estimates total revenues to be approximately $30 million.
For 2012, Ligand currently estimates total revenues to be approximately $30 million.
For earnings history and earnings-related data on Ligand Pharmaceuticals, Inc. (LGND) click here.